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mutations within the nuclear gene OPA1 that encodes for 
a mitochondrial inner membrane protein. The defining 
neuropathological feature is the preferential loss of retinal 
ganglion cells (RGCs) within the inner retina but, rather 
strikingly, the smaller calibre RGCs that constitute the pap-
illomacular bundle are particularly vulnerable, whereas mel-
anopsin-containing RGCs are relatively spared. Although 
the majority of patients with LHON and DOA will present 
with isolated optic nerve involvement, some individuals will 
also develop additional neurological complications pointing 
towards a greater vulnerability of the central nervous sys-
tem (CNS) in susceptible mutation carriers. These so-called 
“plus” phenotypes are mechanistically important as they put 
the loss of RGCs within the broader perspective of neuronal 
loss and mitochondrial dysfunction, highlighting common 
pathways that could be modulated to halt progressive neu-
rodegeneration in other related CNS disorders. The manage-
ment of patients with mitochondrial optic neuropathies still 
remains largely supportive, but the development of effec-
tive disease-modifying treatments is now within tantalis-
ing reach helped by major advances in drug discovery and 
delivery, and targeted genetic manipulation.
Keywords Dominant optic atrophy · Leber 
hereditary optic neuropathy · Mitochondrial diseases · 
Neurodegenerative diseases · OPA1 · Retinal ganglion cell
Introduction
Mitochondrial diseases affect at least 1 in 4300 of the 
population and patients can present with either isolated or 
multisystemic organ involvement [58]. Despite these wide 
phenotypic manifestations, the eye is particularly vulner-
able and over half of all patients will develop significant 
Abstract Mitochondrial optic neuropathies constitute an 
important cause of chronic visual morbidity and registrable 
blindness in both the paediatric and adult population. It is 
a genetically heterogeneous group of disorders caused by 
both mitochondrial DNA (mtDNA) mutations and a grow-
ing list of nuclear genetic defects that invariably affect a 
critical component of the mitochondrial machinery. The two 
classical paradigms are Leber hereditary optic neuropathy 
(LHON), which is a primary mtDNA disorder, and autoso-
mal dominant optic atrophy (DOA) secondary to pathogenic 
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ocular complications, in particular involvement of the 
optic nerve [35, 143]. Unsurprisingly, the risk of blindness 
ranks high on patients’ fears about the prognosis associ-
ated with their specific mitochondrial genetic defect [12, 
74]. The optic nerve consists of the projecting axons from 
about 1.2 million retinal ganglion cells (RGCs) and the 
pathophysiological pathways that drive the selective loss 
of this highly specialised neuronal population are provid-
ing important new insights into the broader link between 
mitochondrial dysfunction and neurodegeneration within 
the central nervous system (CNS) [71]. The two classical 
mitochondrial optic neuropathies are Leber hereditary optic 
neuropathy (LHON) and autosomal dominant optic atrophy 
(DOA), which share overlapping clinical and pathologi-
cal features, despite being caused by mitochondrial DNA 
(mtDNA) point mutations and a growing list of nuclear 
genetic defects, respectively. The defining neuropathologi-
cal feature of LHON and DOA is the early loss of RGCs 
within the papillomacular bundle resulting in an expand-
ing field defect, known as a scotoma, within the patient’s 
central vision [52]. Interestingly, a subgroup of patients can 
develop a syndromic form of LHON and DOA that is char-
acterised by prominent neurological deficits in addition to 
optic atrophy. This review will focus on the disease mecha-
nisms that underpin the selective vulnerability of RGCs 
in mitochondrial optic neuropathies, but also how these 
could relate to the more extensive CNS neurodegenera-
tion observed in patients with the more severe “plus” phe-
notypes. Crucially for patients and their families, there are 
currently limited treatment options and a number of strate-
gies are being considered to prevent or halt neuronal loss in 
this group of disorders, all of which will need to be rigor-
ously assessed for safety and efficacy.
Leber hereditary optic neuropathy
LHON is a primary mitochondrial genetic disorder that 
affects approximately 1 in 30,000 people in the population 
and three point mutations within the mitochondrial genome 
account for over 90 % of cases, namely m.3460G>A 
(MTND1), m.11778G>A (MTND4) and m.14484T>C 
(MTND6) [87]. These three primary mtDNA mutations all 
affect complex I subunits and the disturbed flux of elec-
trons along the mitochondrial respiratory chain results 
in impaired oxidative phosphorylation (OXPHOS) and 
increased levels of reactive oxygen species (ROS) [32]. 
LHON is the classical paradigm of a mitochondrial optic 
neuropathy and the preferential loss of retinal ganglion 
cells (RGCs) raises intriguing questions relating to tissue 
specificity and the secondary modulatory factors that dic-
tate disease expression. The m.11778G>A LHON mutation 
was the first mtDNA variant linked with human disease 
and despite three decades of intensive research, there are 
still several unsolved mysteries, in particular the marked 
incomplete penetrance and the sex bias associated with 
this mitochondrial disorder [134]. Penetrance can vary 
widely between families or even within different branches 
of the same family, but as a rule of thumb, the penetrance 
for a male LHON carrier is ~50 % compared with ~10 % 
for a female LHON carrier [35, 143]. All the evidence so 
far points towards LHON being a complex disease that is 
determined by additional mitochondrial and nuclear genetic 
risk factors as well as environmental triggers such as smok-
ing, which is associated with significantly increased risk of 
visual loss [66, 75, 88]. Oestrogens could also have a neu-
roprotective effect on RGCs and this feature could account, 
at least partly, for the relative protection of female LHON 
carriers against visual loss [55].
Patients with LHON typically present with bilateral sub-
acute loss of central vision and the time course is defined 
by an expanding dense scotoma and a period of worsening 
visual acuities until a nadir is reached. In unilateral cases, 
the fellow eye usually converts within 3-6 months after first 
disease onset (Fig. 1). Spontaneous visual recovery can 
occur, usually in the first year, but the prognosis remains 
guarded with most patients remaining within the legal cri-
teria for blind registration [97]. Limited post-mortem stud-
ies of optic nerves from patients with LHON confirm that 
the neuropathology is limited to the RGC layer [82, 116]. 
The rapid loss of RGCs in the acute phase of the disease is 
thought to be mediated via apoptotic pathways, but further 
work is needed to determine whether the primary site of the 
pathology lies within the cell body or the proximal unmy-
elinated axonal segments. The acute phase of LHON is 
characterised by the early loss of RGCs within the papillo-
macular bundle and this interesting pathological feature has 
been ascribed to their smaller than average axonal calibre 
[118]. The basis for this anatomical vulnerability has been 
modelled using a mathematical equation that integrates the 
surface area (energy demand) and volume (energy supply) 
ratio of the RGC axons, in relation to the amount of ATP 
needed to maintain axonal conduction [101]. It must be 
emphasised that there is no absolute experimental proof, 
but the greater surface area/volume ratio in smaller fibres 
is thought to result in a more limited mitochondrial bioen-
ergetic reserve capacity and proportionally more ROS pro-
duction compared with larger fibres [83].
LHON plus phenotypes
Although the neuropathological hallmark of LHON is 
dominated by the loss of RGCs within the inner retina, a 
subgroup of patients will develop extraocular features as 
part of a more severe LHON “plus” syndromic phenotype 
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Fig. 1  Colour fundus and OCT findings in a patient with acute LHON 
compared with a healthy subject. a An 18-year-old man harbouring the 
m.3460G>A mtDNA mutation who was in the acute stage of LHON 
with onset of visual loss of 1 and 2 months in the right (OD) and left 
eyes (OS), respectively. There are telangiectatic microangiopathy and 
swelling of the peripapillary retinal nerve fibre layer (RNFL) mainly 
involving the superior and inferior quadrants (ONH cube 200 × 200 
protocol, Cirrus HD-OCT, Carl Zeiss Meditec). The left optic disc 
is showing early temporal pallor consistent with the RNFL thin-
ning observed on OCT. The bottom panel shows macular ganglion 
cell layer thinning that is more evident in the left eye (Macular Cube 
512 × 128 protocol). b Comparative images for a healthy subject. 
Please refer to the Supplementary Appendix for a more detailed expla-
nation of the OCT measurements and their anatomical correlates
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[98]. It can be difficult to conclusively ascertain the link 
between a specific neurological feature and a LHON 
mtDNA mutation, but multiple independent case reports 
of patients developing similar syndromic phenotypes on 
the background of different pathogenic LHON mutations 
lend support to a true causal relationship, rather than mere 
coincidence. Dystonia and myoclonus are two movement 
disorders that have been consistently associated with the 
three primary LHON mutations and the development of 
these extraocular features clearly indicates the potential 
for a more generalised neurodegenerative process among 
at-risk LHON carriers [38, 92]. Rarer pathogenic mtDNA 
variants (m.4160T>C, m.11696A>G and/or m.14596T>A, 
and m.14459G>A) in isolated families from Holland, Aus-
tralia and North America have previously been linked with 
particularly severe LHON “plus” phenotypes complicated 
by spastic dystonia, ataxia, juvenile-onset encephalopa-
thy, and psychiatric disturbances [35, 143]. Two mtDNA 
point mutations, m.3376G>A and m.3697G>A, with a 
pronounced inhibitory effect on complex I activity have 
also been identified in patients with an LHON-like optic 
neuropathy and features of the MELAS (mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like epi-
sodes) syndrome [24, 124].
The overlap between LHON and a multiple sclerosis 
(MS)-like illness (Harding disease) is a fascinating asso-
ciation that highlights a potential final common pathway 
linking mitochondrial dysfunction with neuronal loss and 
disease progression in acquired demyelinating disorders 
affecting the central nervous system (CNS). Although 
Harding disease was initially described in a group of 8 
female LHON carriers harbouring the m.11778G>A muta-
tion, this striking combination of visual loss and more gen-
eralised CNS demyelination can affect both sexes, albeit 
with a slight female bias, and it has been reported with the 
m.3460G>A and m.14484T>C mutations as well (Fig. 2) 
[63, 81, 100, 104]. The pattern of visual loss in LHON-
MS appears distinct from classical LHON and demyeli-
nating optic neuritis, being marked by recurrent episodes 
of visual loss that can be associated with ocular pain, but 
with incomplete visual recovery and progression to reg-
istrable blindness in half of all patients [104]. Although 
there is conflicting evidence in the literature, on balance, it 
appears that a primary LHON mutation does not increase 
the risk of developing MS per se, but rather it modulates 
or potentiates the underlying neurodegenerative process in 
an individual who already has a pre-existing predisposition 
to developing clinically definite MS. As LHON-MS repre-
sents a relatively rare subgroup, there is no robust evidence 
base to guide treatment, but given the poor visual prognosis 
and the accumulating visual deficits associated with each 
attack, early disease-modifying therapy to prevent relapses 
and protect the optic nerve seems a pragmatic management 
approach.
Neuromyelitis optica (NMO) is a relatively rare form 
of CNS demyelinating disease among White Caucasians 
Fig. 2  LHON-MS overlap syndrome. T2 MRI images from a 
27-year-old woman with episodes of recurrent optic neuritis over a 
10-year period associated with partial visual recovery. There are dis-
seminated high-signal changes within the white matter regions of the 
brain and cervical spinal cord that are consistent with demyelination 
[105]
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with a prevalence that is 50–100 times lower than that of 
MS [68]. The inflammatory process has a marked pre-
dilection for the optic nerves and the spinal cord and the 
neuropathology is closely linked with a specific autoanti-
body directed against aquaporin-4 (AQP4), which is the 
major water channel in the CNS [103, 138]. After decades 
of debate, clinicopathological studies have revealed strik-
ing differences between NMO and prototypic MS firmly 
establishing the two of them as distinct disease entities 
[23, 95, 113]. It is, therefore, interesting that in addition to 
Harding disease, patients with LHON have been described 
who developed a prominent spinal cord syndrome mim-
icking the radiological and pathological features of NMO 
[91, 122]. Additional research is clearly needed to further 
explore the interplay between a pathogenic LHON muta-
tion, mitochondrial dysfunction and concurrent white mat-
ter CNS demyelinating disease [30, 85].
Autosomal dominant optic atrophy
In contrast to the subacute visual failure observed among 
young adult men in LHON, Poul Kjer described in 1959 
a dominantly inherited bilateral optic neuropathy with an 
indolent course starting in early childhood [76]. Despite 
these major differences in presentation, DOA is also char-
acterised by the marked vulnerability of RGCs within the 
papillomacular bundle, resulting in a central visual field 
defect, impaired colour vision and prominent temporal pal-
lor of the optic disc on fundus examination (Fig. 3) [35, 
143]. DOA affects at least 1 in 25,000 people in the popu-
lation and it is the most common inherited optic neuropa-
thy encountered in clinical practice [142]. The true preva-
lence is likely to be higher due to the marked variability in 
clinical expression and disease progression both within and 
between families. Some mutation carriers present with very 
poor visual function from birth with optic nerve hypoplasia, 
whereas others are visually asymptomatic and they are only 
detected as part of familial contact tracing [15, 42]. The 
natural history of the disease can also be highly variable 
with slowly progressive, sometimes step-like deterioration 
of visual function over time in most patients, whereas for 
others, visual acuity reaches a plateau in early to mid-adult-
hood without any further significant deterioration [41, 142]. 
Although the pattern of visual failure in DOA is relatively 
less severe compared with LHON, the majority of patients 
are eventually registered legally blind and they, therefore, 
need to be counselled appropriately.
The majority (60–70 %) of patients with DOA har-
bour pathogenic mutations in the nuclear gene OPA1 that 
Fig. 3  Colour fundus and OCT findings in DOA. The images were 
obtained from a 20-year-old woman with progressive visual loss start-
ing in early childhood and confirmed to harbour a pathogenic OPA1 
mutation. There is prominent temporal optic disc pallor and marked 
RNFL thinning except in the nasal quadrant, which is relatively 
spared. The disc area analysis reveals small optic discs in both eyes. 
The bottom panel shows pronounced macular ganglion cell layer 
thinning in all sectors. Please refer to the Supplementary Appendix 
for a more detailed explanation of the OCT measurements and their 
anatomical correlates
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encodes for a mitochondrial inner membrane protein with 
multifunctional properties [4, 47]. Over 250 OPA1 muta-
tions have been reported and these can be grouped into two 
major categories depending on whether they are predicted 
to cause disease due to haploinsufficiency (deletions, inser-
tions, splice site and nonsense mutations) or a possible 
dominant-negative mechanism (missense mutations) [50, 
53]. More recently, heterozygous mutations in a number of 
nuclear genes have been identified in patients with DOA, 
including dominant OPA3 mutations in families segre-
gating optic atrophy and early onset cataracts [111]. The 
OPA3 protein is a mitochondrial outer membrane protein 
with pro-fission properties and the loss of RGCs has been 
linked to disturbed mitochondrial dynamics [28]. Interest-
ingly, DRP1 is also a pro-fission cytosolic protein that is 
recruited to the mitochondrial outer membrane, and both 
SPG7 and AFG3L2 encode for mitochondrial AAA pro-
teases that operate as oligomeric complexes to regulate the 
post-translational processing of OPA1 [39, 78, 135]. Rather 
strikingly, with the exception of WFS1, which encodes for 
an endoplasmic reticulum protein, all proteins associated 
with DOA are closely involved in regulating mitochon-
drial dynamics, pointing towards a key biological path-
way essential for RGC maintenance and survival (Table 1) 
[28, 110]. Even with the advent of next-generation whole 
exome and genome sequencing, a proportion of patients 
with optic atrophy and a clear-cut autosomal dominant pat-
tern of inheritance still remain genetically undefined and 
DOA is proving to be much more genetically heterogene-
ous than originally considered.
DOA plus phenotypes
Optic atrophy is the defining feature of DOA, but a spe-
cific missense mutation within the OPA1 gene, c.1334G >A 
(p.Arg455His), has been consistently associated with sen-
sorineural deafness in a number of families [6, 144]. The 
clinical manifestations observed in OPA1 disease have now 
expanded further to include chronic progressive external 
ophthalmoplegia (CPEO) and other extraocular features 
such as ataxia, myopathy and peripheral neuropathy [7, 
13, 65]. In a large multicentre study of 104 patients with 
DOA plus phenotypes from 45 independent families, up to 
20 % of familial OPA1 carriers developed multisystemic 
neuromuscular complications and the risk was signifi-
cantly increased among those harbouring missense OPA1 
mutations, consistent with a putative dominant-negative 
effect [144]. Rather unexpectedly, analysis of muscle biop-
sies obtained from this group of patients revealed mul-
tiple mtDNA deletions and the presence of high levels 
of cytochrome c oxidase (COX)-deficient muscle fibres, 
some of which had marked mitochondrial proliferation in 
the form of ragged-red fibres [125, 144]. The accumula-
tion of mtDNA deletions is a fascinating observation that 
could be due to the accelerated clonal expansion of these 
somatic mutations to sufficiently high levels to trigger 
a biochemical COX defect [102, 146]. CPEO is a classi-
cal manifestation of mitochondrial disease and in keeping 
with the propensity of extraocular muscles to accumulate 
somatic mtDNA mutations at a faster rate compared with 
skeletal muscle, it is perhaps not surprising that about half 
Table 1  Nuclear mitochondrial disorders with prominent optic nerve involvement
Inheritance Locus Gene OMIM Phenotype
Dominant 1p36.2 MFN2 601,152 Hereditary motor and sensory neuropathy type 6 (HMSN-6, CMT2A)
3q28-q29 OPA1 165,500 Isolated optic atrophy and syndromic dominant optic atrophy (DOA plus)
4p16.1 WFS1 614,296 Wolfram syndrome spectrum disorders
12p11.21 DRP1 614,388 Optic atrophy and abnormal brain development
19q13.2-q13.3 OPA3 165,300 Autosomal dominant optic atrophy and early-onset cataracts (ADOAC)
Recessive 3q26.33 DNAJC19 610,198 DCMA syndrome ± optic atrophy
4p16.1 WFS1 222,300 Wolfram syndrome 1
4q24 CISD2 604,928 Wolfram syndrome 2
5q.22.1 SLC25A46 616,505 Optic atrophy ± peripheral neuropathy/cerebellar syndrome
6q21 RTN4IP1 616,732 Optic atrophy ± cerebellar syndrome/mental retardation/epilepsy
9q13-q21.1 FXN 229,300 Friedreich ataxia
11q14.1-q21 TMEM126A 612,989 Optic atrophy ± auditory neuropathy
12q24.31 C12orf65 615,035 Optic atrophy ± spastic paraplegia/peripheral neuropathy
16q24.3 SPG7 607,259 Hereditary spastic paraplegia type 7 (HSP-7)
19q13.2-q13.3 OPA3 258,501 Type III 3-methylglutaconic aciduria (Costeff syndrome)
22q13.2 ACO2 616,289 Optic atrophy ± cerebellar syndrome/encephalopathy
Xq22.1 TIMM8A 304,700 Mohr-Tranebjaerg syndrome ± optic atrophy
795Acta Neuropathol (2016) 132:789–806 
1 3
of all patients with DOA plus phenotypes develop ptosis 
and ophthalmoplegia in later life [59, 145].
Similar to Harding disease in LHON, OPA1 mutation 
carriers can also develop an MS-like illness where the optic 
atrophy occurs on the background of a more disseminated 
inflammatory process with neuroradiological and serologi-
cal features, consistent with MS [133, 147]. It is intriguing 
that both LHON and DOA share this specific association 
and the contribution of the underlying pathogenic mtDNA 
or OPA1 mutation in driving CNS neurodegeneration 
deserves further study. The association of optic atrophy 
with spastic paraplegia, resembling cases that fit the histori-
cal description of Behr syndrome, has been well described 
in several unrelated OPA1 mutation carriers [26, 37, 90]. 
The development of this syndromic form of DOA has 
been ascribed to the deleterious synergistic consequences 
of compound heterozygous OPA1 mutations, in particular 
the recurrent c.1146A>G (p.Ile382Met) missense mutation, 
which can occur in combination with a deep intronic muta-
tion [25]. Remarkably, two Italian families carrying dif-
ferent OPA1 missense mutations have been reported with 
an atypical combination of parkinsonism, dementia and 
CPEO, but with only subclinical optic neuropathy [34]. 
More recently, a compound homozygous OPA1 mutation 
has been identified for the first time in two affected Jew-
ish sisters from consanguineous parents who developed a 
fatal infantile encephalomyopathy with hypertrophic car-
diomyopathy and optic atrophy [123]. However, instead 
of multiple mtDNA deletions, the muscle biopsy from one 
sister showed marked mtDNA depletion. The expanding 
clinical and genetic heterogeneity linked to DOA plus phe-
notypes only serves to emphasise the more global neurode-
generative impact of pathogenic OPA1 mutations that can 
extend far beyond the inner retina and the anterior visual 
pathways. There is now a considerable body of evidence 
linking mitochondrial dysfunction with late-onset neurode-
generative disorders, such as Alzheimer disease and Parkin-
son disease, indicating a common pathological thread and 
a close relationship with mitochondrial structure, function 
and localisation [28].
A syndromic form of optic atrophy reminiscent of DOA 
plus can arise from dominant mutations in the MFN2 gene, 
which encodes for a mitochondrial outer membrane pro-
tein [109, 115]. MFN2 coordinates mitochondrial fusion by 
working in close tandem with its fellow fusogenic protein, 
OPA1, and analogous to the observation in muscle biopsies 
from patients carrying OPA1 mutations, MFN2 mutations 
can also precipitate mtDNA instability with either the accu-
mulation of multiple mtDNA deletions or mtDNA deple-
tion. MtDNA maintenance is clearly intrinsically linked 
to the delicate balance between mitochondrial fusion and 
fission and adding further weight to this hypothesis, SPG7 
and AFG3L2 mutations have now been reported in patients 
with ataxic disorders complicated by CPEO and optic atro-
phy, and with evidence of multiple mtDNA deletions in 
skeletal muscle biopsy specimens [57, 105]. Nuclear genes 
that are directly or indirectly involved in regulating mito-
chondrial dynamics and the faithful replication of the mito-
chondrial genome can, therefore, lead to varying degrees 
of CNS neurodegeneration, but with the optic nerve being 
invariably the most sensitive affected end organ [31].
Other mitochondrial optic neuropathies
Autosomal recessive and X-linked optic neuropathies are 
relatively rare, but an increasing number of disease causing 
genes are being identified with wider access to molecular 
genetic testing and next-generation sequencing platforms 
(Table 1). TMEM126A, which encodes for a mitochondrial 
inner membrane protein of unclear function, was the first 
gene to be found in patients with non-syndromic recessive 
optic atrophy, although it can also occur in combination 
with peripheral neuropathy in some mutation carriers [62]. 
Other genes associated with both isolated and syndromic 
forms of recessive optic atrophy include: (1) ACO2, which 
encodes for an enzyme of the tricarboxylic acid cycle [93]; 
(2) RTN4IP1, which encodes for a mitochondrial outer 
membrane protein that interacts with the endoplasmic 
reticulum protein RTN4 (or NOGO) to regulate neuronal 
dendritic branching [9]; (3) WFS1 (Wolfram syndrome 1), 
which encodes for Wolframin, a transmembrane endoplas-
mic reticulum protein that plays a critical role in calcium 
homeostasis and interorganellar cross-talk at mitochondria-
associated membranes (MAMs) [28, 126]; and (4) CISD2 
(Wolfram syndrome 2), which encodes for Miner 1, a 
redox-active iron-sulphur cluster protein that regulates the 
unfolded protein response and calcium homeostasis [136]. 
The molecular elucidation of both forms of Wolfram syn-
drome has uncovered the intimate dynamic interactions 
between mitochondria and the endoplasmic reticulum, and 
how dysfunction in one compartment can detrimentally dis-
turb the other, and vice versa.
The occurrence of visual pathway involvement has 
become much better appreciated in the inherited ataxias 
and peripheral neuropathy syndromes. Friedreich Ataxia 
(FRDA) is the most common form of hereditary ataxia and 
it is due to recessive mutations in the FXN gene, which 
encodes for a mitochondrial protein involved in the biosyn-
thetic pathways of iron-sulphur clusters [143]. The latter are 
essential components of aconitase and the mitochondrial 
respiratory chain complexes I, II and III, and their com-
bined dysfunction probably contributes to the development 
of optic neuropathy, which is now a well-recognised feature 
of FRDA [51]. Costeff Syndrome or type III 3-methylgluta-
conic aciduria (MGA) is a rare neurodegenerative disorder 
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characterised by ataxia, spastic paraplegia, extrapyramidal 
dysfunction, cognitive deficits and optic atrophy, and it is 
almost exclusively seen in patients of Iraqi Jewish descent 
harbouring recessive OPA3 mutations [10].
Charcot–Marie–Tooth (CMT) disease is one of the 
most common inherited neurological disorders, affecting 
approximately 1 in 2500 people in developed countries. A 
long list of causative genes have been identified, includ-
ing MFN2, which can cause both recessive and dominant 
axonal CMT2A. In one particular subtype of CMT2A, 
referred to as hereditary motor and sensory neuropathy type 
6 (HMSN6), dominant MFN2 mutations result in visual 
failure secondary to optic atrophy in addition to the more 
typical axonal peripheral neuropathy [149, 150]. Prompted 
by this phenotypic association, other inherited forms of 
optic atrophy associated with CMT disease have been 
recently described with recessive mutations in SLC25A46 
[1] and C12orf65 [107]. It should also be noted that both 
SLC25A46 and C12orf65 mutations can also result in a 
much more severe neurodegenerative Leigh-like presenta-
tion [11, 64, 69].
The Mohr-Tranebjaerg syndrome (deafness-dystonia-
optic atrophy) is associated with recessive mutations 
affecting the TIMM8A gene on the X-chromosome, which 
encodes for a translocase of the mitochondrial inner 
membrane (TIMM) [70]. Visual failure in this disorder is 
thought to be due to global involvement of the visual path-
ways, extending as far back as the visual cortex [130]. A 
similar mechanism of altered protein import through the 
mitochondrial inner membrane has also been postulated 
for the DCMA (dilated cardiomyopathy with ataxia) syn-
drome, which is caused by mutations in the DNAJC19 
gene, and optic atrophy has been reported in some cases 
[45].
Neurodegeneration: histopathological studies
The number of post-mortem studies for patients with mito-
chondrial optic neuropathies is limited and some histori-
cal reports date back to the pre-molecular era [2, 116]. For 
LHON, histopathological studies of multiple tissues includ-
ing the retina, optic nerve and brain are rare and none have 
been performed during the acute stage of the disease [36]. 
Notwithstanding these practical limitations, there is severe 
loss of RGCs and marked thinning of the retinal nerve fibre 
layer (RNFL), but the remaining retinal structure is other-
wise preserved [73, 119]. Electron microscopy carried out 
on optic nerve cross-sections has also highlighted promi-
nent demyelinating features in the chronic stage of LHON 
with only a thin covering of myelin found around the 
remaining axons (Fig. 4) [36]. Comprehensive brain histo-
pathology has been reported for an affected m.14484T>C 
LHON carrier with an MS overlap syndrome and a spec-
trum of neuropathological changes was observed, including 
demyelinating plaques within the brain white matter and 
optic nerves, and prominent vacuolation and cystic necro-
sis throughout the CNS [81]. As expected from the clinical 
features, post-mortem studies of optic nerves from patients 
with DOA confirmed the preferential loss of RGCs with 
evidence of axonal demyelination and gliosis [72, 77]. In 
contrast to the widespread loss of RGCs in patients with 
LHON and DOA, an evolutionary ancient RGC subtype 
that expresses the photopigment melanopsin (mRGCs) 
seems relatively immune to mitochondrial dysfunction 
and impaired mitochondrial dynamics. These mRGCs are 
highly specialised circadian photoreceptors that project 
to the hypothalamus and their preservation in LHON and 
DOA likely explains the maintenance of the pupillary light 
reflex even in those patients with severe visual impairment 
(Fig. 4) [82, 96].
Neurodegeneration: in vivo imaging
Major advances in bioimaging technology have allowed 
unprecedented high-resolution images of the brain, visual 
pathways and retinal structures to be captured for analysis. 
In vivo techniques such as magnetic resonance spectros-
copy (MRS) and optical coherence tomography (OCT) are 
non-invasive and well tolerated, and they provide stand-
ardised tools that have been used to document the chronol-
ogy and pattern of tissue loss in both the acute and chronic 
stages of LHON [19, 21, 121]. Based on longitudinal OCT 
studies, swelling of the RGC axons along the inferotempo-
ral segment of the optic disc seems to occur prior to the 
onset of visual loss and following disease conversion, a 
wave of RNFL swelling then spreads circumferentially 
to involve the remaining quadrants (Fig. 1) [16]. As optic 
atrophy ensues, there is global thinning of the peripapillary 
RNFL although some patients can exhibit relative sparing 
of the nasal quadrant in the chronic stage. High-resolution 
spectral domain macular OCT imaging has provided fur-
ther insight into the pattern of RGC loss in LHON. Inter-
estingly, in patients presenting with first eye involvement, 
the macular ganglion cell and inner plexiform layer (GC-
IPL) and the macular RNFL already showed pathological 
thinning in the presymptomatic stage about 6 weeks before 
the onset of visual loss in the fellow eye. Maximal GC-IPL 
thinning was reached by 6 months and this OCT parameter 
could, therefore, prove to be a more sensitive biomarker 
of optic nerve damage compared with peripapillary RNFL 
measurements where progressive thinning continues until 
at least 12 months after the first onset of visual loss [14].
OCT studies in cohorts of patients harbouring patho-
genic OPA1 mutations have shown a differential pattern 
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of RNFL thinning, which was more severe in the temporal 
quadrant and less pronounced in the nasal quadrant (Fig. 3) 
[20, 140]. Importantly, OPA1 mutations were associated 
with a significantly smaller optic nerve head and although 
speculative, this congenital hypoplasia could result from 
dysregulated apoptosis in early development and an accel-
erated loss of RGCs in utero. As for LHON, macular GC-
IPL thickness measurements could prove a more useful 
structural biomarker that correlates better with visual acu-
ity loss compared with peripapillary RNFL values [18]. 
Another observation made possible by high-resolution 
OCT imaging is the documentation of microcystic macular 
changes in the inner nuclear layer of patients with LHON 
and DOA [17, 29]. These retinal abnormalities are not asso-
ciated with leakage on fluorescein angiography and they 
have been attributed to focal retinal schisis induced by vit-
reous traction on the background of severe RNFL atrophy. 
Similar microcystic macular changes have previously been 
described in patients with demyelinating optic neuritis and 
a possible aetiological link was made with the severity of 
the underlying inflammatory process [54]. More recently, 
lamination of the outer plexiform layer has been observed 
in patients with optic atrophy caused by dominant, but not 
recessive, WFS1 mutations, and this peculiar OCT char-
acteristic could be due to Müller cell dysfunction and dis-
turbed calcium homoeostasis [86].
MRI tractography studies indicate that the loss of RGCs 
in the anterior visual pathway could result in transsynap-
tic degeneration that extends from the lateral geniculate 
nucleus to the optic radiations, as reported previously in 
other optic neuropathies such as demyelinating optic neu-
ritis and glaucoma [22, 89]. More widespread microstruc-
tural white matter changes in mitochondrial optic neu-
ropathies have also become more clearly apparent with the 
application of high-resolution MRI scanners and diffusion 
tensor (DT) imaging protocols to study cohorts of patients 
with LHON and OPA1-related DOA, which is consistent 
with the known white matter sensitivity to mitochondrial 
respiratory chain dysfunction [89, 94, 112, 114]. Further-
more, the pattern of DT MRI abnormalities and the lowered 
diffusivity in the white matter skeleton of the cerebellum, 
brainstem, thalamus and fronto-occipital-temporal lobes 
Fig. 4  Melanopsin-expressing retinal ganglion cells and myelin 
ultrastructure. a Retinal cross-sections from a healthy control indi-
vidual were stained with antibody against melanopsin. The inner ret-
ina shows the ganglion cell layer with retinal ganglion cells (arrows) 
and one melanopsin-expressing retinal ganglion cell (asterisk). b The 
inner retina from a patient with LHON reveals a melanopsin-express-
ing retinal ganglion cell (asterisk) in the complete absence of other 
retinal ganglion cells. c Electron micrograph of optic nerve cross-
sections from a healthy control individual showing densely packed 
axons with variable axonal calibre and normal myelin thickness. d A 
representative illustration from a patient with LHON highlights the 
dramatic depletion of axons with a thin myelin coating around the 
surviving axons
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could reflect increased fragmentation of the mitochondrial 
network and altered neuronal dendritic arborization [112]. 
Proton magnetic resonance spectroscopy (1H-MRS) has 
also shown that raised lactate and reduced creatine (Cr) and 
N-acetylaspartate (NAA) levels can occur not only in areas 
of abnormal signal changes, but also in normal appearing 
white matter regions, indicative of a generalised mitochon-
drial metabolic deficit within the CNS [99, 114]. In terms 
of their clinical relevance, the neuroradiological changes 
observed in patients with mitochondrial optic neuropathies 
could prove useful surrogate biomarkers for the spectrum 
of white matter neuropathological abnormalities observed 
in mitochondrial disease, which can range from mild atro-
phy to extensive vacuolation with a sieve-like appearance 
depending on the severity of the underlying mitochondrial 
dysfunction [132].
Disease mechanisms
The unique susceptibility of RGCs in mitochondrial optic 
neuropathies still remains a puzzling mystery and although 
several hypotheses have been put forward, none has been 
conclusively demonstrated [35, 143]. The highly special-
ised anatomical and physiological properties of RGCs are 
likely to be relevant, namely their relatively high metabolic 
requirements due to sustained spiking activity; the constant 
exposure to potentially damaging light; the sharp 90-degree 
bend as their axons exit the eye at the lamina cribosa; and 
the relatively long unmyelinated intraocular portion that 
necessitates a high density of packed mitochondria for effi-
cient signal conduction [8, 27]. Faced with these multiple 
constraints, it should therefore not come as a surprise that 
mitochondria in neurones have evolved specific adapta-
tions to survive in such a challenging environmental niche. 
The RGC body is located within the inner retina and its 
dense dendritic arborization together with its long axonal 
projection to the lateral geniculate nucleus places peculiar 
demands on cellular mitochondria. They must be able to 
cluster at synapses to deliver sufficient quantities of ATP 
locally and altering the delicate balance between mitochon-
drial fusion and fission is essential to meet the cell’s fluctu-
ating bioenergetic demands, in addition to supporting bidi-
rectional transport along dendrites and axon [31]. Clearly, 
the disruption of critical pro-fusion proteins, such as OPA1 
and MFN2, or a direct impact on complex I subunits as 
in LHON will have profound negative consequences on 
mitochondrial function with reduced ATP production and 
elevated ROS levels [28]. There is still an ongoing debate 
whether the determining factor that drives RGC loss in 
mitochondrial optic neuropathies is primarily due to a bio-
energetic crisis or toxic ROS levels, or possibly with both 
factors having a synergistic deleterious effect [83].
To further disentangle the complex neurodegenera-
tive pathways that underpin this group of inherited optic 
nerve disorders, a number of in vitro approaches have 
been employed and the effort of several research groups 
worldwide has led to the generation of faithful animal 
models for both LHON and DOA [28, 84]. Heterozygous 
Opa1+/− mutant mice recapitulate the progressive RGC 
loss and optic nerve degeneration observed in the human 
form of the disease and the experimental data indicate that 
multiple pathways are involved that contribute to impaired 
mitochondrial oxidative phosphorylation, disturbed mito-
chondrial dynamics, increased ROS generation and, ulti-
mately, a heightened susceptibility to undergo apoptosis 
[3, 40, 46, 120]. Immunolabelling of retinal flat-mount 
preparations obtained from Opa1+/− mutant mice showed 
dendritic pruning of ON-centre RGCs from 10 months of 
age with a significant reduction in total dendritic length 
and surface area (Fig. 5). Synaptic connectivity imaged 
after biolistic labelling of RGCs also showed reduced 
synaptic density on the distal ends of the dendritic tree 
[137]. Among the Opa1 mouse models that have been 
established, there is also a suggestion that some of the 
mutant mice can develop extraocular features analogous 
to the more severe syndromic “plus” phenotypes observed 
in a proportion of patients with DOA. In addition to inner 
retinal and optic nerve degeneration, more widespread 
neuropathological and psychophysical abnormalities have 
been noted in subgroups of Opa1+/− mutant mice, includ-
ing enlarged lateral ventricles within the brain, disorgan-
ised myofibres in skeletal and cardiac muscle, locomotive 
and ataxic gait disturbance, and decreased auditory brain-
stem responses [4, 40, 120].
Other cellular mechanisms that have gained increasing 
attention in the context of mitochondrial optic neuropa-
thies are mtDNA maintenance and mitophagy, and the 
cross-talk with the endoplasmic reticulum at MAM inter-
faces [28, 129]. The accumulation of somatic mtDNA 
deletions in post-mitotic tissues of patients carrying OPA1 
mutations points towards an impaired mtDNA replica-
tion machinery and there is a suggestion that OPA1 could 
be part of the physical structure that anchors nucleoids to 
the mitochondrial inner membrane [48]. Another possible 
explanation for the clonal expansion of somatic mtDNA 
deletions is the inability to remove these dysfunctional 
mtDNA species through mitophagy [34, 102]. The occur-
rence of optic atrophy in the context of pathogenic MFN2, 
WFS1 and CISD2 mutations provides strong supportive 
evidence that RGC survival is detrimentally affected as a 
result of impaired interactions between the mitochondrial 
network and the endoplasmic reticulum, especially if there 
is disturbed calcium flux between these compartments [28]. 
Although much has been learnt over the years, all the above 
observations still do not fully explain the marked clinical 
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variability and tissue specificity seen in mitochondrial optic 
neuropathies, and dissecting these complex mechanistic 
questions holds the key to more effective targeted therapeu-
tic strategies [141]. Rightly so, the early focus has been on 
the molecular genetics, but now there is an urgent need to 
capitalise on the greater availability of more sophisticated 
technological platforms to compare the transcriptomic, pro-
teomic and metabolomic profiles between different pheno-
typic groups to look for potential clues or biomarkers that 
might explain the variable disease penetrance and progno-
sis for patients with mitochondrial optic neuropathies [44, 
131].
Therapeutic strategies
The management of patients with mitochondrial optic neu-
ropathies remains largely supportive with the provision of 
visual rehabilitation and genetic counselling [106, 148]. 
There are a number of technical and logistical challenges in 
developing effective disease-modifying treatments aimed at 
rescuing RGCs, namely the need to bypass the blood brain 
barrier to achieve a high enough local concentration of the 
drug; the limited therapeutic window posed by the massive 
early loss of RGCs in subacute disorders such as LHON; 
the limited availability of sensitive optic nerve biomarkers; 
and, crucially, the substantial financial resources needed 
to conduct an adequately powered treatment trial. Despite 
these difficulties, the eye is an easily accessible organ for 
direct surgical intervention and it benefits from relative 
immune privilege.
One obvious therapeutic approach is to improve the 
flux of high energy electrons along the mitochondrial res-
piratory chain and bypass any blockage in more proximal 
complexes. Ubiquinone is a fat-soluble molecule present 
at a very high concentration within the inner mitochondrial 
membrane and it has the advantageous property of trans-
ferring electrons efficiently from complexes I and II to 
complex III [60]. Co-enzyme Q10 (CoQ10) is a synthetic 
ubiquinone analogue and despite the limited evidence 
base, it is frequently prescribed to patients with mitochon-
drial disease. Idebenone and EPI-743 are newer generation 
shorter-chain analogues of ubiquinone and, unlike CoQ10, 
they can cross the blood brain barrier, which makes them 
theoretically more potent as antioxidants [106]. There is 
supporting evidence that idebenone can improve the visual 
prognosis, albeit, partially, in a subgroup of patients that are 
treated relatively early in the acute stage of LHON [33, 79, 
80]. EPI-743 has also shown promise in a small case series 
of five patients with acute LHON treated within 90 days of 
disease conversion, but a randomised placebo-controlled 
trial is needed to fully explore its true therapeutic potential 
[117]. In addition to antioxidants, boosting mitochondrial 
biogenesis and ATP synthesis is an attractive complemen-
tary strategy that could help rescue failing neuronal cells 
from apoptotic cell death. A number of drugs, such as 
bezafibrate, rosiglitazone, 5-aminoimidazole-4-carboxam-
ide ribonucleoside (AICAR), acetyl-L-carnitine (ALCAR), 
vitamin B3, and oestrogen-like molecules, have been iden-
tified as effective inducers of mitochondrial proliferation 
under conditions of metabolic stress and their effectiveness 
in rescuing the optic nerve phenotype or the neurological 
Fig. 5  Dendropathy in a mouse model of dominant optic atrophy. a 
Flat-mounted retinas were labelled with the fluorescent marker DiI 
and individual RGCs were imaged with confocal microscopy. A rep-
resentative RGC from a 16-month-old wild-type mouse is shown that 
demonstrates the extensive arborization of the dendritic tree. b An 
age-matched RGC from a B6;C3-Opa1Q285STOP mutant mouse har-
bouring a nonsense mutation in the OPA1 gene. There is marked den-
dritic pruning characterised by a reduction in total dendritic length 
and field area
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manifestations of LHON and DOA deserve to be studied 
further [106, 148].
Direct mitochondrial gene therapy is challenging due to 
the constraints imposed by the organelle’s physical struc-
ture and the presence of a relatively impervious inner mito-
chondrial membrane. A possible approach to circumvent 
these technical difficulties is allotopic gene expression 
where the gene of interest is transferred into the nuclear 
genome and the replacement protein product is engi-
neered with a specific targeting sequence that facilitates its 
uptake into the mitochondrial compartment [139]. Promis-
ing pre-clinical data based on in vitro and rodent models 
have resulted in the recent launch of pivotal clinical trials 
for patients harbouring the m.11778G>A mutation that 
involves the intravitreal injection of a modified adeno-
associated virus (AAV) vector carrying the replacement 
MTND4 subunit gene (NCT02652767, NCT02652780 
and NCT02161380, https://clinicaltrials.gov/ct2/home, 
accessed on 28 August 2016) [49, 61]. An alternative, but 
complementary, approach is to modify the AAV construct 
to carry a gene whose protein product has a neuroprotec-
tive effect and enhances the survival of dysfunctional neu-
rones. Proof of principle has been demonstrated with the 
overexpression of SOD2, which encodes for superoxide 
dismutase and serves to boost the cell’s antioxidant defence 
mechanisms [108]. These more generic neuroprotective 
approaches are attractive as they could be applied not only 
to rescue RGCs, but also other central neuronal populations 
in patients manifesting the more generalised “plus” phe-
notypes. There are still multiple challenges that need to be 
overcome to achieve a higher efficiency of RGC transfec-
tion and sustained transgene expression, but gene therapy 
programmes for mitochondrial optic neuropathies caused 
by dominant OPA1 and recessive WFS1 mutations are cur-
rently in development, which will hopefully lead to early 
phase clinical trials.
The coming decade will bring together a conflu-
ence of major advances in cell-based and genomic edit-
ing technologies that hold the potential to revolutionise 
our approach to the prevention and treatment of human 
genetic diseases [139]. The ability to reprogram post-
mitotic somatic cells into induced pluripotent stem cells 
(iPSCs) has been a major breakthrough and the ability 
to produce patient-specific neuronal populations, includ-
ing RGCs, opens up not only the possibility of personal-
ised regenerative medicine, but in the shorter term, high-
throughput drug screening on the diseased cells of interest 
can be actively exploited. Although the RGC layer is eas-
ily accessible, multisystem neurological involvement rep-
resents a major challenge and another strand of research 
has focused on the prevention of disease transmission 
from mother to child. There is an estimated 2300 women 
of childbearing age in the United Kingdom that harbour 
pathogenic mtDNA mutations and by using the national 
fertility rate, about 150 newborn per year would be at 
high risk of developing severe mitochondrial disease [56]. 
A pioneering therapeutic approach is to use conventional 
IVF techniques to transfer the parental nuclear genetic 
material into a donor egg containing a normal wild-type 
mtDNA population such that the child’s entire genetic 
make-up will be derived from the biological parents 
except for the 37 mitochondrial genes. Pronuclear trans-
fer and metaphase II spindle transfer are the two tech-
niques that are currently being refined and further exper-
imental work will hopefully validate the safety of these 
potentially groundbreaking mitochondrial replacement 
strategies [43, 67, 127, 128]. Following a wide-ranging 
public consultation, in February 2015, both Houses of 
Parliament in the United Kingdom have voted strongly 
in favour of mitochondrial donation to prevent the mater-
nal transmission of mitochondrial disease (http://www.
wellcome.ac.uk/About-us/Policy/Spotlight-issues/Mito-
chondrial-diseases/, accessed on 28 August 2016). Safety 
must remain the primary concern at all times and tight 
regulations must be agreed and implemented at national 
and international levels to avoid misuse of these promis-
ing, but as yet unproven, methods aimed at preventing the 
maternal transmission of pathogenic mtDNA mutations to 
the next generation.
Conclusions
All the causative genes identified so far in patients with 
inherited optic neuropathies result in mitochondrial dys-
function and it is abundantly clear that RGCs are exqui-
sitely sensitive to even minor disturbances in mitochon-
drial biogenesis or dynamics, with an innate susceptibility 
to undergo apoptosis under conditions of heightened cel-
lular stress and elevated ROS levels. It is still difficult to 
fully unravel the individual contribution of these often 
overlapping pathophysiological mechanisms but, never-
theless, they do provide a number of targets amenable to 
therapeutic modulation. The pace of gene discovery will 
continue to accelerate with the advent of next-generation 
sequencing technologies, providing not only a confirmed 
molecular diagnosis to patients and their families, but also 
important insights into new protein mediators that regu-
lar RGC and neuronal survival. The stark reality is that 
the majority of patients with mitochondrial optic neuropa-
thies are registered legally blind and the translational gap 
for this group of disorders remains to be bridged. How-
ever, all the signs point towards a turning point and the 
availability of better disease models coupled with innova-
tion in bioimaging, drug discovery and genetic manipu-
lation brings renewed hope that clinicians will soon be 
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in a position to better monitor disease progression and 
improve the visual prognosis of patients with mitochon-
drial optic neuropathies.
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